Tocilizumab in the treatment of adult rheumatoid arthritis.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Immunotherapy

• Publication date

  2018-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/imt-2017-0173PMID 29495891
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period

  2018cited by this paper
• Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics’ register GISEA

  2018cited by this paper
• A review of sarilumab for the treatment of rheumatoid arthritis.

  2018cited by this paper
• Radiographic joint damage in early rheumatoid arthritis patients: comparing tocilizumab- and methotrexate-based treat-to-target strategies

  2018cited by this paper
• Tapering versus steady-state methotrexate in combination with tocilizumab for rheumatoid arthritis: a randomized, double-blind trial

  2018cited by this paper
• Short‐course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation

  2017cited by this paper
• Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden

  2017cited by this paper
• Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long‐Term Clinical Trial Safety Data in Rheumatoid Arthritis

  2017cited by this paper
• Risk factors of serious infections in patients with rheumatoid arthritis treated with tocilizumab in the French Registry REGATE

  2017cited by this paper
• Safety profile of biological therapies for treating rheumatoid arthritis

  2017cited by this paper
• Lipoprotein(a) concentrations in rheumatoid arthritis on biologic therapy: Results from the CARdiovascular in rheuMAtology study project.

  2017cited by this paper
• Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials

  2017cited by this paper
• Effects of tocilizumab on neutrophil function and kinetics

  2017cited by this paper
• The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.

  2017cited by this paper
• Sirukumab: a promising therapy for rheumatoid arthritis

  2017cited by this paper
• Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis.

  2017cited by this paper
• The emerging safety profile of JAK inhibitors in rheumatic disease

  2017cited by this paper
• Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study

  2017cited by this paper
• SAT0183 Clinical remission in subjects with rheumatoid arthritis treated with subcutaneous tocilizumab as monotherapy or in combination with methotrexate or other synthetic dmards: a real-world clinical trial (tospace)

  2017cited by this paper
• The role of IL-6 in host defence against infections: immunobiology and clinical implications

  2017cited by this paper
• Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study

  2017cited by this paper
• Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)

  2016cited by this paper
• Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

  2016cited by this paper
• Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments

  2016cited by this paper
• The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation

  2016cited by this paper
• Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review

  2016cited by this paper
• Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis

  2016cited by this paper
• Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study

  2016cited by this paper
• Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials

  2016cited by this paper
• Pharmacokinetic and Pharmacodynamic Analysis of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis From 2 Randomized, Controlled Trials: SUMMACTA and BREVACTA

  2016cited by this paper
• Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data.

  2016cited by this paper
• Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis

  2016cited by this paper
• 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

  2016cited by this paper
• ROUTINE-a prospective, multicentre, non-interventional, observational study to evaluate the safety and effectiveness of intravenous tocilizumab for the treatment of active rheumatoid arthritis in daily practice in Germany.

  2016cited by this paper
• Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.

  2016cited by this paper
• Relationship Between Baseline and Early Changes in C‐Reactive Protein and Interleukin‐6 Levels and Clinical Response to Tocilizumab in Rheumatoid Arthritis

  2016cited by this paper
• Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice.

  2016cited by this paper
• Rheumatoid arthritis

  2016cited by this paper
• Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

  2016cited by this paper
• Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab

  2016cited by this paper
• Low immunogenicity of tocilizumab in patients with rheumatoid arthritis

  2016cited by this paper
• Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade.

  2016cited by this paper
• Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

  2016cited by this paper
• Response to Tocilizumab in Rheumatoid Arthritis Is Not Influenced by the Body Mass Index of the Patient

  2015cited by this paper
• Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice

  2015cited by this paper
• Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials

  2015cited by this paper
• 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis.

  2015cited by this paper
• FRI0163 Smoking Status Does not Seem to Affect Tocilizumab Efficacy in RA Patients

  2015cited by this paper
• Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study.

  2015cited by this paper
• Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study

  2015cited by this paper
• Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial

  2015cited by this paper
• Therapeutic uses of anti-interleukin-6 receptor antibody.

  2015cited by this paper
• Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis

  2015cited by this paper
• Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.

  2015cited by this paper
• An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy

  2015cited by this paper
• Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study

  2015cited by this paper
• Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry.

  2015cited by this paper
• Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study

  2014cited by this paper
• Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo.

  2014cited by this paper
• Tocilizumab in the treatment of rheumatoid arthritis and beyond

  2014cited by this paper
• Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis

  2014cited by this paper
• Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis

  2014cited by this paper
• Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)

  2014cited by this paper
• Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis

  2014cited by this paper
• Prediction of Therapeutic Responses to Tocilizumab in Patients With Rheumatoid Arthritis: Biomarkers Identified by Analysis of Gene Expression in Peripheral Blood Mononuclear Cells Using Genome‐Wide DNA Microarray

  2014cited by this paper
• Tocilizumab as monotherapy or in combination with nonbiologic disease‐modifying antirheumatic drugs: Twenty‐four–week results of an open‐label, clinical practice study

  2013cited by this paper
• Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure

  2013cited by this paper
• A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)

  2013cited by this paper
• Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.

  2013cited by this paper
• Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study

  2013cited by this paper
• Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

  2013cited by this paper
• Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches.

  2013cited by this paper
• Exposure‐Exposure Relationship of Tocilizumab, an Anti–IL‐6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis

  2013cited by this paper
• Pathways for Bone Loss in Inflammatory Disease

  2012cited by this paper
• Extended Co-Expression of Inhibitory Receptors by Human CD8 T-Cells Depending on Differentiation, Antigen-Specificity and Anatomical Localization

  2012cited by this paper
• Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice

  2012cited by this paper
• Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study

  2012cited by this paper
• Clinical and epidemiological research

  2011cited by this paper
• Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register - Commentary

  2011cited by this paper
• Integrated safety in tocilizumab clinical trials

  2011cited by this paper
• Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year.

  2011cited by this paper
• Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review

  2011cited by this paper
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

  2010cited by this paper
• [Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis].

  2010cited by this paper
• The role of Interleukin 6 in the pathophysiology of rheumatoid arthritis

  2010cited by this paper
• Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis

  2010cited by this paper
• Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.

  2010cited by this paper
• Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab bef

  2009cited by this paper
• Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

  2009cited by this paper
• Utilization Trends of Tumor Necrosis Factor Inhibitors Among Patients with Rheumatoid Arthritis in a United States Observational Cohort Study

  2009cited by this paper
• Humanized antihuman IL-6 receptor antibody, tocilizumab.

  2008cited by this paper
• Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease.

  2008cited by this paper
• Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

  2008cited by this paper
• Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

  2008cited by this paper
• IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

  2008cited by this paper
• Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.

  2008cited by this paper
• Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

  2008cited by this paper
• Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab

  2007cited by this paper
• The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

  2006cited by this paper
• Interleukin-6: from basic science to medicine--40 years in immunology.

  2005cited by this paper

• Case Report: Intra-articular injection of tocilizumab for arthritis treatment in chronic graft-vs.-host disease

  2025cites this paper
• The impact of tocilizumab on hepatic enzyme levels in rheumatoid arthritis patients: a narrative review

  2025cites this paper
• A randomized, double-blind, single-dose, parallel two-group study comparing the pharmacokinetics, safety, and immunogenicity of BAT1806 SC with tocilizumab in healthy Chinese male subjects

  2025cites this paper
• Potential role of PAR2 inhibitors for treating rheumatoid arthritis

  2025cites this paper
• Chromatin accessibility variation provides insights into missing regulation underlying immune-mediated diseases

  2024cites this paper
• Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis.

  2023cites this paper
• Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.

  2023cites this paper
• Low-dose IL-2 therapy in autoimmune diseases: An update review

  2023cites this paper
• PROSPECTS FOR INNOVATIVE DRUGS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

  2023cites this paper
• Signaling pathways in rheumatoid arthritis: implications for targeted therapy

  2023cites this paper
• Clinical Management of Critical COVID-19 Patients: Insights from the Literature and “On the Field” Experience

  2020cites this paper
• Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome

  2020cites this paper
• RMHP_A_265030 1999..2010

  2020cites this paper
• The Protective Effect of Different Polar Solvent Extracts of Er Miao San on Rats with Adjuvant Arthritis

  2020cites this paper
• Evaluation of dose-tapering strategies for intravenous tocilizumab in rheumatoid arthritis patients using model-based pharmacokinetic/pharmacodynamic simulations

  2020cites this paper
• The Imperfect Cytokine Storm

  2020cites this paper
• COVID-19 Drug Treatment in China

  2020cites this paper
• Full Issue PDF

  2020cites this paper
• New era of therapy for endocrine autoimmune disorders

  2020cites this paper
• The potential anti-inflammatory and anti-nociceptive effects of rat hemopressin (PVNFKFLSH) in experimental arthritis.

  2020cites this paper
• Current Options in the Treatment of COVID-19: A Review

  2020cites this paper
• Exposure‐response modeling of tocilizumab in rheumatoid arthritis using continuous composite measures and their individual components

  2019cites this paper
• Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy

  2019cites this paper
• Biologics: A Therapy of New Era

  2018cites this paper